alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 51 studies with an author at Chinese Academy of Medical Sciences & Peking Union Medical College (CN) (page 1 of 3) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

✓ Peer-reviewed alzhub usefulness score 74 out of 100. Lancet (London, England) 2021-01-08

After multivariable adjustment, patients showed an odds ratio (OR) 1·61 (95% CI 0·80-3·25) for scale 4 versus scale 3 and 4·60 (1·85-11·48) for scale 5-6 versus scale 3 for diffusion impairment; OR 0·88 (0·66-1·17) for scale 4 versus scale 3 and OR 1·77 (1·05-2·97) for scale 5-6 versus scale 3 for anxiety or depression, and OR 0·74 (0·58-0·96) for scale 4 versus scale 3 and 2·69 (1·46-4·96) for scale 5-6 versus scale 3 for fatigue or muscle weakness. 2 key findings →

Design: cohort study Participants: 94 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

AI-based differential diagnosis of dementia etiologies on multimodal data

✓ Peer-reviewed alzhub usefulness score 71 out of 100. Nature medicine 2024-07-04

Differential diagnosis of dementia remains a challenge in neurology due to symptom overlap across etiologies, yet it is crucial for formulating early, personalized management strategies. 1 key finding →

Participants: 51,269 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Confounder adjustment in observational studies investigating multiple risk factors: a methodological study

✓ Peer-reviewed alzhub usefulness score 64 out of 100. BMC Medicine 2025-03-04

A total of 162 studies were included, with 88 (54.3%) exploring potential risk factors and 74 (45.7%) examining specific risk factors. 5 key findings →

Design: case-control study Participants: 162 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Development and validation of an interpretable deep learning framework for Alzheimer's disease classification

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Brain : a journal of neurology 2020-06-01

Alzheimer's disease is the primary cause of dementia worldwide, with an increasing morbidity burden that may outstrip diagnosis and management capacity as the population ages. 5 key findings →

Participants: 417 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cerebrospinal fluid Aβ42, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Fluids and barriers of the CNS 2017-05-10

The purpose of this systematic review and meta-analysis was to evaluate the performance of cerebrospinal fluid (CSF) beta amyloid 42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) as potential diagnostic biomarkers for idiopathic normal-pressure hydrocephalus (iNPH) and to assess their utility indistinguishing patients with iNPH from those with Alzheimer disease (AD) and healthy normal controls. 4 key findings →

Design: systematic review Participants: 413 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Supporting Informal Dementia Caregivers Through an iSupport Web-Based Primary Health Care Intervention: Hybrid Effectiveness-Implementation Mixed Methods Study

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Journal of Medical Internet Research 2025-09-09

The intervention revealed no substantial between-group differences in caregiver burden (β=-3.80, 95% CI -11.25 to 3.65, P=.32), quality of life (β=-1.55, 95% CI -6.59 to 3.49, P=.55), or social support (β=0.85, 95% CI -2.86 to 4.56, P=.65). 5 key findings →

Design: randomized controlled trial Participants: 60 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Is dietary choline intake related to dementia and Alzheimer's disease risks? Results from the Framingham Heart Study

✓ Peer-reviewed alzhub usefulness score 59 out of 100. The American journal of clinical nutrition 2022-11-01

The positive association of choline for cognition has been reported in both animal and human studies, yet the associations of choline with the risks of incident dementia or Alzheimer's disease (AD) in humans is unclear. 4 key findings →

Participants: 3,224 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors

✓ Peer-reviewed alzhub usefulness score 57 out of 100. The Lancet. Neurology 2008-07-28

Despite mortality due to communicable diseases, poverty, and human conflicts, dementia incidence is destined to increase in the developing world in tandem with the ageing population. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Plasma p-tau181 Level Predicts Neurodegeneration and Progression to Alzheimer's Dementia: A Longitudinal Study

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Frontiers in neurology 2021-09-07

Plasma-based biomarkers would be potential biomarkers for early diagnosis of Alzheimer's disease (AD) because they are more available and cost-effective than cerebrospinal fluid (CSF) or neuroimaging. 4 key findings →

Design: cross-sectional Participants: 185 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Altered Gut Microbial Metabolites in Amnestic Mild Cognitive Impairment and Alzheimer's Disease: Signals in Host-Microbe Interplay

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Nutrients 2021-01-14

Intimate metabolic host-microbiome crosstalk regulates immune, metabolic, and neuronal response in health and disease, yet remains untapped for biomarkers or intervention for disease. 2 key findings →

Participants: 77 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Prevalence of dementia in rural China: impact of age, gender and education

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Acta neurologica Scandinavica 2006-10-01

The prevalence of dementia in this population is similar to that reported from other areas in mainland China and Taiwan with aging being a significant risk factor. 3 key findings →

Design: cross-sectional Participants: 16,095 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Effect of depression on risks of Alzheimer’s disease and vascular dementia: A real-world longitudinal study

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Psychiatry Research 2025-09-02

During an average follow-up of 3.63 years, we observed a total of 1 493 individuals developing dementia among 4 341 depressed and 43 214 matched non-depressed individuals (62.4% female; mean [SD] age at baseline 64.4 [11.1] years). 5 key findings →

Design: longitudinal study Participants: 493 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes

✓ Peer-reviewed alzhub usefulness score 53 out of 100. JAMA Network Open 2019-03-01

Among 45 029 participants undergoing cognitive assessment, mean (SD) age was 67.9 (8.0) years; 80.7% were men. 5 key findings →

Participants: 1,197 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Developing a machine learning model for detecting depression, anxiety, and apathy in older adults with mild cognitive impairment using speech and facial expressions: A cross-sectional observational study

✓ Peer-reviewed alzhub usefulness score 52 out of 100. International journal of nursing studies 2023-07-07

The machine learning model developed in this study demonstrated strong classification performance in detecting and differentiating depression, anxiety, and apathy. 3 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cerebral small vessel disease burden relates to cognitive decline via impaired amyloid clearance in the general population

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of Cerebral Blood Flow & Metabolism 2026-04-10

Our aim is to examine the interplay between cerebral small vessel disease (CSVD) pathology, Alzheimer’s disease (AD) related amyloid-β (Aβ) clearance, and cognition in general population. 2 key findings →

Design: cross-sectional Participants: 1,026 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Long-Term Exposure to PM 2.5 Constituents, Genetic Susceptibility, and Incident Dementia: A Prospective Cohort Study among 0.2 Million Older Adults

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Environmental Science & Technology 2025-02-25

Fine particulate matter, known as PM 2.5, is recognized as a risk factor for dementia. 1 key finding →

Participants: 217,336 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Retinal biomarkers in cognitive impairment and dementia: Structural, functional, and molecular insights

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Alzheimer s & Dementia 2025-09-01

Cognitive impairment and dementia, including Alzheimer's disease (AD), pose a global health crisis, necessitating non-invasive biomarkers for early detection. 1 key finding →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Trajectories of general and central obesity beyond middle age in relation to late‐life cognitive decline and dementia

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Obesity 2025-01-28

General and central obesity trajectories beyond midlife with persistently high or increasing patterns were significantly associated with an increased risk of developing cognitive decline and dementia in late life. 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed